Real-world applications of PARPi maintenance therapy for recurrent ovarian cancer: A single-center study in China

• Published in: Gynecologic oncology Vol. 170; pp. 25 - 31
• Main Authors: Wang, Deng-Feng, Shi, Xun-Wei, Zhang, Can, Zhang, Jie, Liu, Hong, Huang, Jian-Ming, Zhang, Guo-Nan, Wen, Qing-Lian
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2023
• Subjects: Carcinoma, Ovarian Epithelial - drug therapy; Female; Humans; Maintenance therapy; Neoplasm Recurrence, Local - drug therapy; Ovarian neoplasms; Ovarian Neoplasms - drug therapy; PARPi; Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use; Prognosis; Progression-free survival; Retrospective Studies; Prognosis; PARPi; Ovarian neoplasms; Maintenance therapy; Progression-free survival
• ISSN: 0090-8258; 1095-6859
• DOI: 10.1016/j.ygyno.2022.12.014

To assess the actual clinical application of poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) maintenance therapy in Chinese patients with recurrent ovarian cancer, and to explore prognostic factors associated with progression-free survival (PFS). We retrospectively assessed real-world clinical data from our hospital using the inclusion and exclusion criteria of representative randomized controlled trials, analyzed the prognosis, and performed univariate and multivariate analyses of prognostic factors. Between 2019 and 2022, the proportion of platinum-sensitive recurrence ovarian cancer patients who received PARPi maintenance therapy increased to 29.6%, 53.3%, 43.8% and 62.2%, respectively, each year. A total of 48 patients were included in the prognostic analysis, of which 32 and 16 received olaparib and niraparib, respectively. Using the criteria of the Study19 and SOLO2 studies, the olaparib group in our patients had coincidence rates of 56.3% and 18.8%, respectively. Using the criteria of the NOVA and NORA studies, the niraparib group had coincidence rates of 31.3% and 37.5%, respectively. Median PFS was 26.1 months (95% CI 20.2–32.1). Response to primary therapy was an independent prognostic factor for PFS (relative risk, 3.248; 95% CI 1.081–9.757, P = 0.036). PARPi maintenance therapy was also effective in real world applications. Complete response (CR) to primary therapy was an independent factor favorably affecting PFS. Therefore, primary treatment choices aimed at optimal cytoreduction during primary surgery and improving the CR rate should still be considered, which positively affects the long-term prognosis of patients in the new treatment mode. •From 2019 to 2022, the proportion of PSR maintenance therapy with PARPi increased from 29.6% to 62.2%.•There were substantial differences between the patients in actual clinical settings and the RCTs population.•The mPFS was 26.1 months in a real-world study regarding PARPi maintenance therapy in recurrent ovarian cancer patients.•CR to the primary therapy was the independent factor favorably affecting PFS in the new treatment mode.